Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NVS: Novartis AG -- Ignore unavailable to you. Want to Upgrade?

To: puborectalis who wrote (80)	10/10/2003 1:58:28 PM
From: Starlight	Read Replies (1) \| Respond to of 116

Yesterday's news about Femara, which dramatically increases the survival rate of breast cancer patients, should get some attention from investors. It's a story that is being told on all major news networks, and if this were a more widely followed US stock, the stock price would be soaring. biz.yahoo.com Press Release Source: Novartis Compelling Disease Free Survival Results in Adjuvant Breast Cancer Trial Prompt Independent Researchers to Offer Trial Patients the Opportunity to Switch to Femara(R), as Reported in New England Journal of Medicine Thursday October 9, 11:33 am ET Interim results from first study to explore post-tamoxifen use of Femara(R) (letrozole tablets) in postmenopausal women with early breast cancer showed significantly reduced risk of recurrence (43%) and improved disease-free survival